Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Bracco Imaging is demonstrating how its customized evidence-based diagnostic imaging solutions are meeting the demands of an evolving radiology market at RSNA-2010 annual meeting.

Bracco Imaging S.p.A. – one of the world’s leading companies in the imaging agent business and part of the Bracco Group – is demonstrating how its customized evidence-based diagnostic imaging solutions are meeting the demands of an evolving radiology market at the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America ( RSNA ), which is being held November 28 - December 3, 2010 at Chicago’s McCormick Place, booth #4035.

Bracco continues to build on its longstanding commitment to safety, efficacy and efficiency at this year’s meeting, where the company is sharing clinical and scientific insights as well as regulatory progress related to its contrast media in Computed Tomography ( CT ), Magnetic Resonance Imaging ( MRI ), Nuclear Medicine , Cardiac Catheterization, and Interventional/Diagnostic Radiology, and its contrast delivery systems.

“A number of factors are shaping the evolution of radiology today, including rapid innovation, cost control and an acute awareness of product safety,” said Carlo Medici, Head of Global Commercial Operations of Bracco Imaging S.p.A. and President and Chief Executive Officer, Bracco Diagnostics Inc. “By listening to the individual radiologist and focusing on evidence-based solutions for a more rapid, accurate diagnosis, Bracco is pursuing new standards for safety, efficacy and efficiency in diagnostic imaging.”

From the development of the first modern nonionic contrast agent in 1981 to the integration of protocols and contrast delivery platforms showcased at RSNA-2010 , customer-driven innovation is a hallmark of Bracco’s integrated solutions approach.

Bracco’s diagnostic imaging products have outpaced growth in key areas due to its focus on high quality processes and products that are in tune with the needs of patients, physicians and the broader healthcare market. A defining example of this commitment is Isovue (iopamidol injection), a product whose supporting clinical evidence, versatile indications and availability in a convenient range of iodine concentrations and packaging options have made it the number-one low osmolar contrast media agent in the U.S.1,2

The company also continues to see robust growth stemming from products and solutions related to its 2008 acquisition of E-Z-EM, Inc., one of the most recognized brands among radiologists and gastrointestinal (GI) physicians across several markets including CT Contrast, Delivery Systems, Workflow Solutions and Virtual Colonoscopy. Among these are the company’s injector and data management systems, which enable radiologists, administrators and technologists to gain workflow efficiencies, imaging optimization and patient safety benefits. Also, through this acquisition, Bracco is now the only provider of barium-based oral imaging products.

Source: BUSINESS WIRE